ReviewJournal of clinical and experimental dentistry2025
In-vivo Studies on Sustained Release Systems for Delivering Antimycotics. A Systematic Review focused on Oral Candidiasis treatment.
Review in Journal of clinical and experimental dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral candidiasis (OC) is the most common infection in patients wearing polymer-based dentures. Sustained-release systems for delivery (SRSDs) have been proposed as anti-OC therapeutics. Therefore, this systematic review aimed to determine which SRDS showed better antifungal results in in vivo models. Material and Methods: Electronic literature searches were conducted using PubMed/MEDLINE, Web of Science, and Google Scholar databases, limited to January 1, 1989, to May 31, 2025. The MeSH terms (PubMed) utilized included drug delivery systems, phytochemicals, plant extracts, herbal medicines, phytometabolites, antifungal agents, azoles, nystatin, macrolides, Candida spp., oral candidiasis, oral candidosis, Candida albicans, and Candida glabrata. Articles were included whose experimental design was in vivo or ex vivo models and whose objective was to determine the efficacy of sustained release systems as an anti-Candida treatment. Results: A total of 137 articles were retrieved and 125 were discarded because they did not match the principal objective of the study or did not meet the inclusion criteria. Twelve observational studies involving humans (adults aged 18 years) or animal models exposed to antifungal SRDSs were included. The most frequently used SRDSs were buccal mucoadhesive gel, mucoadhesive buccal tablets, and nanoparticles, while the most commonly used biomaterials were the bioadhesive polymers HPMC, NaCMC, carbopol 934, and sodium alginate. All antifungals incorporated in the SRDSs showed antifungal efficiency. Conclusions: Chitosan-coated bioadhesive polymers are the most promising options for treating OC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.